A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Adverum Appoints Rabia Gurses Ozden, MD, as Chief Medical Officer
Author: Jennie Crabbe
Adverum Biotechnologies announced June 11 that it had appointed Rabia Gurses Ozden, MD, as chief medical officer.
Ozden is stepping down from the seat she held on Adverum’s board. Retina specialist Szilárd Kiss, MD, will fill the seat.
Ozden most recently served as chief medical officer of Ocular Therapeutix. Before that, she served as chief development officer at gene therapy company Akouos. She was also chief medical officer of Nightstar Therapeutics, which was acquired by Biogen.
Ozden received her medical degree from Turkey’s Hacettepe University School of Medicine and completed her ophthalmology residency at Ankara University School of Medicine and her clinical fellowship in glaucoma at the New York Eye and Ear Infirmary.
Adverum, of Redwood City, California, is developing Ixo-vec (ixoberogene soroparvovec, also known as ADVM-022), a gene therapy candidate for wet age-related macular degeneration (AMD) that is designed to produce sustained therapeutic levels of aflibercept in the eye.
The candidate, which is in Phase II study, has been granted Innovation Passport status in the UK; PRIME (Priority Medicines) status in the EU; and fast track status in the US.